LYCA · Lycia Therapeutics, Inc. · Documents
Market Cap
$1.56B
Shares
52.09M
Volume · Oct 23
2.29M
Avg daily vol (1 sessions)
2.29M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| S-1/A | Lycia Therapeutics, Inc. is offering 14,700,000 shares at an expected $16.00 to $18.00 per share for its initial public offering and Nasdaq listing under “LYCA.” LCA-0061 showed a mean maximum IgE reduction of 96% from baseline. | 2026-10-20 | — | |
| S-1 | Lycia Therapeutics, Inc. is pursuing an initial public offering and Nasdaq Global Market listing under “LYCA.” Phase 1 data for LCA-0061 showed a mean maximum IgE reduction of 96% after a single 70 mg dose, while LCA-0321 is in Phase 1 for Graves’ disease. | 2026-10-05 | — |
Showing 1–2 of 2 filings